Research and Markets: Cervical Cancer - Pipeline Review, H1 2015
September 03 2015 - 8:51AM
Business Wire
Research and Markets
(http://www.researchandmarkets.com/research/plzl7p/cervical_cancer)
has announced the addition of the "Cervical Cancer - Pipeline
Review, H1 2015" report to their offering.
This report provides comprehensive information on the
therapeutic development for Cervical Cancer, complete with
comparative analysis at various stages, therapeutics assessment by
drug target, mechanism of action (MoA), route of administration
(RoA) and molecule type, along with latest updates, and featured
news and press releases. It also reviews key players involved in
the therapeutic development for Cervical Cancer and special
features on late-stage and discontinued projects.
This report features investigational drugs from across the globe
covering over 20 therapy areas and nearly 3,000 indications. The
report is built using data and information sourced from proprietary
databases, Company/University websites, SEC filings, investor
presentations and featured press releases from company/university
sites and industry-specific third party sources. Drug
profiles/records featured in the report undergo periodic updates
following a stringent set of processes that ensures that all the
profiles are updated with the latest set of information.
Additionally, processes including live news & deals tracking,
browser based alert-box and clinical trials registries tracking
ensure that the most recent developments are captured on a real
time basis.
Reasons to Buy
- Provides strategically significant competitor information,
analysis, and insights to formulate effective R&D development
strategies
- Identify emerging players with potentially strong product
portfolio and create effective counter-strategies to gain
competitive advantage
- Develop strategic initiatives by understanding the focus areas
of leading companies
- Identify and understand important and diverse types of
therapeutics under development
- Plan mergers and acquisitions effectively by identifying key
players of the most promising pipeline
- Devise corrective measures for pipeline projects by
understanding Cervical Cancer pipeline depth and focus of
Indication therapeutics
- Develop and design in-licensing and out-licensing strategies
by identifying prospective partners with the most attractive
projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued
projects and understanding the factors that drove them from
pipeline
Companies Mentioned
- 3SBio
- Admedus
- Advaxis
- Amorfix Life Sciences
- Antigen Express
- Arbor Vita
- AstraZeneca
- AVEO Pharmaceuticals
- Azaya Therapeutics
- Cancer Research Technology
- Chong Kun Dang Pharmaceutical
- Critical Outcome Technologies
- CZ BioMed
- Daiichi Sankyo Company
- EyeGene
- F. Hoffmann-La Roche
- Formune
- Genexine
... and many more.
Full list available at
http://www.researchandmarkets.com/research/plzl7p/cervical_cancer
View source
version on businesswire.com: http://www.businesswire.com/news/home/20150903005776/en/
Research and MarketsLaura Wood, Senior
Managerpress@researchandmarkets.comFor E.S.T Office Hours Call
1-917-300-0470For U.S./CAN Toll Free Call 1-800-526-8630For GMT
Office Hours Call +353-1-416-8900U.S. Fax: 646-607-1907Fax (outside
U.S.): +353-1-481-1716Sector: Oncology